Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Humanigen Inc (HGEND)

Humanigen Inc (HGEND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 438,755
  • Shares Outstanding, K 42,188
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta -2.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.85
Trade HGEND with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 10/26/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.5000 +38.67%
on 09/10/20
18.2500 -43.01%
on 08/19/20
-7.3000 (-41.24%)
since 08/17/20
3-Month
7.5000 +38.67%
on 09/10/20
33.9500 -69.37%
on 07/28/20
-10.3500 (-49.88%)
since 06/17/20
52-Week
1.5000 +593.33%
on 01/14/20
33.9500 -69.37%
on 07/28/20
+6.3000 (+153.66%)
since 09/17/19

Most Recent Stories

More News
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”

BURLINGAME, CA / ACCESSWIRE / September 17, 2020 / Humanigen, Inc. ("Humanigen") (OTCQB:HGEND)(NASDAQ:HGEN), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response...

JPM : 192.14 (+1.44%)
HGEND : 10.4000 (+15.56%)
HGEN : 0.0002 (-84.62%)
Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”

Humanigen, Inc. (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab,...

HGEND : 10.4000 (+15.56%)
HGEN : 0.0002 (-84.62%)
Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq

Humanigen, Inc. (HGEND) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate...

HGEND : 10.4000 (+15.56%)
Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQ

BURLINGAME, CA / ACCESSWIRE / September 15, 2020 / Humanigen, Inc. (OTCQB:HGEND) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called...

JPM : 192.14 (+1.44%)
HGEND : 10.4000 (+15.56%)
Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab

- Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020 - Commercial manufacturing to begin in 2021 at Lonza's manufacturing facility at...

GILD : 67.03 (+0.12%)
HGEND : 10.4000 (+15.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Humanigen, Inc. is a biopharmaceutical company. It focuses on advancing medicines for patients with neglected and rare diseases. The Company's product candidate principally consists of benznidazole, lenzilumab and ifabotuzumab. Humanigen Inc., formerly known as KaloBios Pharmaceuticals Inc., is based...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 11.3400
1st Resistance Point 10.8700
Last Price 10.4000
1st Support Level 9.4600
2nd Support Level 8.5200
3rd Support Level N/A

See More

52-Week High 33.9500
Fibonacci 61.8% 21.5541
Fibonacci 50% 17.7250
Fibonacci 38.2% 13.8959
Last Price 10.4000
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar